nanoform
small is powerful®

Nanoform Management Presentation

Q2 2023 Interim Report

August 24th, 2023

Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this presentation are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2022 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this presentation represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

SHORT INTRODUCTION TO NANOFORM

Nanoform in a Snapshot

The Share

- Listed June 4th, 2020, on Nasdaq First North Premier Growth Market in Helsinki and Stockholm
- Tickers: NANOFH and NANOFS
- Significant Nordic, European and US institutional ownership
- All press releases: https://nanoform.com/en/section/media/press-releases/

Nanoform

- Global experts in nanotechnology and drug particle engineering
- ~160 employees, ~30 nationalities, ~35 with PhD degree
- Headquartered in Finland with additional senior staff and board members in Denmark, France, Portugal, Sweden, UK, and US
- ~4000m^2 manufacturing site in Helsinki for nanoforming API's

Strong balance sheet:

- EUR 57m (SEK 670) cash
- No debt

Platform Technology

- CESS® technology for small molecules
- BIO technology for large molecules
- STARMAP® for picking winners through cutting-edge sparse-data AI
- Unique formulation expertise for nanomedicine development

API = Active Pharmaceutical Ingredient
CESS® = Controlled Expansion of Supercritical Solutions

The structural pharma R&D problem

Less than 50 drugs approved in the US annually on average…

Annual number of novel drug approvals by FDA 2010-2022



…while the global pharma industry R&D expenditure exceeds $200B

Global pharmaceutical R&D spending 2014-2028E (USDbn)



➢ **A game changer is needed to improve R&D yield**

Source: U.S. Food and Drug Administration (FDA); IQVIA Institute for Human Data Science; Statista; Nature

Low bioavailability is the key issue

Poor bioavailability and low efficacy most common reasons for drug failure

Reasons for drug failure in pre-clinical trials (share of molecules)



Majority of new drugs suffer from poor solubility



➢ **Nanoform can enhance the pharma industry output by targeting poorly soluble drugs**

Source: GlobalData 2009, Cutting Edge Water-based Nanotechnology in Drug Development (Reasons for drug failure); Nikolakakis & Partheniadis (2017), Self-Emulsifying Granules and Pellets: Composition and Formation Mechanisms for Instant or Controlled Release (Share of poorly soluble drugs) 1) Classification of drug substance according to Biopharmaceutics Classification System (BCS)

Particle size is key

Smaller particle size can improve a drug's bioavailability



- The surface area increases 30 fold from a 10 micron[1] sized particle once the particle size is reduced to 100nm
- Reduction of particle size down to 50nm increases the surface area by 1,000 fold



Pre-nanoforming

Post-nanoforming

- Smaller particles have a larger surface area
- Larger surface area of particles enables better bioavailability of a drug
- Improved bioavailability implies better absorption of a drug by the body's circular system
- CESS® can produce API with large surface areas which can significantly improve the bioavailability of drugs

CESS® produced nanoparticles have a larger surface area and as such improved bioavailability.

Small Molecules - Proprietary technology

Green technology

Controlled Expansion of Supercritical Solutions - CESS®



1. Supercritical CO_2 is guided into a pressure vessel loaded with API
2. Increasing the pressure and temperature in the vessel dissolves the API in supercritical CO_2
3. The CO_2 and the API are released from the pressure vessel and the flow, pressure and temperature profiles are accurately controlled
4. The pressure and temperature is controlled to achieve a stable nucleation phase and formation of nanoparticles
5. In a collection vessel the CO_2 is sublimated resulting in final nanoparticles ready for collection and formulation

➢ **Relatively simple process developed through combining deep knowledge in physics, chemistry, and pharma**

Small molecules - Small is powerful®



Large molecules – Small is now possible in biologics too

Our unique biological nanoforming technology can produce drug particles as small as 50 nm in diameter while retaining biological activity. It is a gentle bottom-up process, and its effectiveness has been demonstrated on peptides and proteins in the 1 kDa* – 150 kDa range. We can engineer particle sizes to specific requirements. Our advanced technology can be applied across the biologics field to potentially:

*1 kDa = One thousand daltons. A dalton is the weight of a hydrogen atom. Kilodalton is the standard unit used to represent the weight of large molecules such as proteins.

Large molecules - Proprietary technology

Green technology

Nanoforming process for biologics

1. API containing feed solution is pumped into the nebulizer
2. Feed solution is nebulized into a carrier gas
3. Mist is transported into the drying chamber via a connection pipe
4. Mist is dried using low-temperature drying gas
5. Dried particles are charged by the ionizer and collected using electrostatic precipitation



API = active pharmaceutical ingredient
Nebulization = turns liquid into mist
Ionization = particles electrically charged

Nanoform is here to fill the gap

The solution to low bioavailability is to decrease the particle size of the Active Pharmaceutical Ingredient (API)

Giving unsuccessful drug candidates a second chance

> 58,000 failed drugs in the last 40 years*

Improving existing drugs

> 5,800 existing drugs*

Enabling new drugs

> 20,000 drugs in development*

Nanoform's CESS® is the only technology that can manufacture nanoparticles without solvents, excipients, and complex production processes

API = Active Pharmaceutical Ingredient
CESS® = Controlled Expansion of Supercritical Solutions
**Source: Nanoform and Pharmaprojects® | Informa, 2022*

Simplified value chain

High level overview of Nanoform's value chain and business model



Clients

- Global large pharma
- Mid-sized and specialty pharma
- Biotech

Launch of new drugs, improving existing drugs & reducing clinical attrition

nanoform
small is powerful®

Revenue

- Fixed fee per project
- Royalty as a % based on drug sales or supply price per kg

➢ Nanoform nanoforms APIs for the pharma and biotech industry using its patented CESS® technology

API = Active Pharmaceutical Ingredient
CESS® = Controlled Expansion of Supercritical Solutions
GMP = Good Manufacturing Practice

CEO REVIEW

A record 11 new customer projects signed in Q2 and targeting first license/commercial supply agreement in 2024

A record 11 new customer projects in Q2.

GMP manufacture for “Project Blockbuster" is being completed.

Targeted timeline for one or several license/commercial supply agreements in 2024.

Marketing Authorization application submitted to FIMEA*.

For Nanoforming of API’s to be used in products with a Marketing Authorization.

Operating free cash flow continues to improve.

Received notice of allowance from US Patent & Trademark Office for our US biologics patent application.

Conducted promising initial *in-vitro* trials with two major pharma companies looking at monoclonal antibodies.

**Fimea = Finnish Medicines Agency*

Project Blockbuster – a potential game changer for Nanoform



Project Blockbuster: The development and commercialization of a more patient centric and nanoformed version of an existing blockbuster drug.

Nanoform near-term business targets 2023

Topic	Target	Status
Customer Projects	*" Increased number of non-GMP and GMP projects signed in 2023 vs 2022 " **	*On track*
Operating Free Cashflow	*" Improved operating free cashflow in 2023 vs 2022 " ***	*On track*

GMP = Good Manufacturing Practice
** 17 non-GMP and 1 GMP projects signed in 2022*
*** Operating free cash flow EUR -28m in 2022*

Nanoform mid-term business targets 2025

>70
new APIs per year

35 lines of which 7-14 are GMP compliant

200-250
employees

>90%
gross margin

Cash flow positive


COMMERCIAL

Revenue drivers & industry attrition rates

Nanoform pre-clinical and clinical revenue drivers

	Non-GMP	GMP
Proof of Concept (PoC)	➢ # of active customers ➢ # of APIs per customer ➢ Price per PoC per API	
Phase I, II & III and/or 505(b)(2)		➢ Attrition between previous and current phase ➢ Price per phase per API ➢ Time lag between previous and current phase ➢ # of customers with 505(b)(2) strategy ➢ Proportion of new drug candidates and 505(b)(2) APIs
Proof of Process (PoP)	➢ Attrition between PoC and PoP ➢ Price per PoP per API ➢ Time lag between PoC and PoP	
Drugs on the market		➢ # of drugs on the market using CESS® ➢ License fee & royalty level per drug ➢ Net revenues per drug ➢ Time lag Phase II and market (505b2) ➢ Time lag Phase III and market ➢ Speed of uptake on market

Global Pharmaceutical industry's pre-clinical and clinical success rates



Timeline (years)	Pre-clinical	Phase I	Phase II	Phase III	Approval	Total
New drugs	~1-4	~2	~2	~3-4	~1	~9-13
Existing drugs	-	Clinical development for 505(b)(2) ~2-5			~1	~3-6

Source: Company information; Takebe, Imai & Ono (2018), Clinical and Translational Science (11) (Pre-clinical to Phase I); Biotechnology Innovation Organization, Biomedtracker and Amplion, Clinical Development Success Rates 2006-2015 (Clinical success rates); Kaur, Sharma & Sharma (2014), Journal of Drug Delivery and & Therapeutics (4) (Timeline); The Pharmaceutical Journal, Drug Development: The Journey of a Medicine from Lab to Shelf (Timeline); Camargo Pharmaceutical Services, Understanding the 505(b)(2) Approval Pathway (Timeline); 1) Non-NMEs often use 505(b)(2) pathway to gain FDA approval, source: Biotechnology Innovation Organization, Biomedtracker and Amplion 2) Academic drug discovery, NME consisting only of small molecules

Nanoform – Attractive revenue model, stands the test of time

Predictable revenue streams through capitalizing the entire pharmaceuticals value chain

Phase	Proof of Concept / Proof of Process	Phase I – III trials	Drugs on the market
Certification	Non-GMP	GMP	GMP
Description	➢ *Proof of concept study* - assessment of the possibility to nanoform a specific API ➢ *Proof of process study* - definition of parameters to establish the optimal process and controls for a specific API	➢ API for clinical trials are manufactured in Nanoforms GMP facility ➢ Supply of material for customers' Phase I, II and III trials ➢ Nanoform gets paid regardless of the outcome of the trials	➢ Drugs that have passed the trials and reached commercialization ➢ In practice, if a company has taken its drug through Phase II trials, it is difficult to switch manufacturer ➢ Significant potential from patent extension (505b2 projects) of drugs already on the market
Revenue model	Fixed fee per project *Estimated project fee of EUR 50-500k per API per project*	Fixed fee per project *Estimated project fee of EUR 0.5-10m per API per phase*	Royalty as a % on drug sales or supply price per kg *Estimated royalty fee of 1-20%*

➢ **Attractive business model with diversified risk profile due to not having to carry the cost & risk of drug development or being dependent on a single drug**

Global drug R&D pipeline size and growth



Global number of companies with active pipelines



Strong project intake

17 new projects signed in H1, both with new and repeat customers

Commercial Relationships 2019 to Q2 2023

10 major pharma companies

1 co-development

3 collaborations



26 mid-sized, specialty pharma & biotech companies

6 new clients in H1 (3 new clients in Q1 and 3 new clients in Q2)

A *Selection* of Nanoform Pharmaceutical Partnerships

10 of the top 20 Major Pharma and many Biotechs including

AstraZeneca

Boehringer Ingelheim

GSK

SANOFI

Pharmanovia

TARGTEX
TARGETED THERAPEUTICS

NACUITY PHARMACEUTICALS, INC

BILL & MELINDA GATES *foundation*

Celanese

APRECIA
THE 3DP PHARMACEUTICAL COMPANY®

Monoclonal Antibodies' (mAb's)



Small is a powerful ingredient in formulation

Celanese

- **Nanoform and Celanese collaboration demonstrated significant reduction in the *initial burst effect* seen commonly in high drug load implants by combining Nanoform's CESS® particles with Celanese's Celanese VitalDose® EVA copolymer delivery technology for drug-eluting implants.**
- **We also demonstrated that nanoformed particles can enable longer sustained release properties for *long-acting drug products* and *smaller implants*.**
- **Celanese case study:** https://nanoform.com/en/nanoform-and-celanese-use-drug-nanoparticles-to-modify-the-release-kinetics-of-ethylene-vinyl-acetate-long-acting-implants/

TargTex

- **Customer TargTex hit another important milestone in July.**
- **TargTex had a *pre-IND meeting with the FDA* to discuss its glioblastoma program with Nanoformed API.**
- **The *positive feedback from the FDA* clarifies the regulatory path towards taking the treatment to the clinic**
- **Nanoform's Collaboration with TargTex video:** https://nanoform.com/en/nanoforms-collaboration-with-targtex-2/

Project Blockbuster – a potential game changer for Nanoform



Project Blockbuster: The development and commercialization of a more patient centric and nanoformed version of an existing blockbuster drug.

Q2 2023 FINANCIALS

Nr of employees & nr of lines





GMP lines 2&3 will be commissioned after inspection by Fimea, expected later in 2023.

Customer momentum returned in 4Q22 and has continued





which led to record signings in 2Q23





Rolling 6 month signings back at growth trend





Our Experience, Expertise & Efficiency continues its fast growth



Cumulatively we have >10 000hrs of experience running nanoforming lines

Revenue recognized impacted by slow signings in 2H22, marginal impact on rolling 12m





Nr of projects generating revenue*





***Impact on revenue can in a quarter for some of the projects be negative if budgeted costs increase significantly (often related to hours worked).**

Project Blockbuster has led to increased external GMP QC cost





Excluding the cost of external GMP QC services, related to the Blockbuster project, our underlying materials & services costs have remained between EUR 30-60k per quarter. In June, Nanoform submitted a notification to the Finnish Medicines Agency (Fimea) to update our Manufacturer's Authorization (MIA). The notification included our new Quality Control laboratory (GMP QC) and an inspection is expected to take place later in 2023. This will help our gross margin return to the 90+ levels we target.

IT expenses has fallen back after successful SAP implementation





Improvement in operating free cash flow continued in 2Q





Financial KPI's

EUR thousand	4-6/2023	4-6/2022	1-6/2023	1-6/2022	1-12/2022	1-12/2021	1-12/2020
Revenue	780	890	1,524	1,650	3,487	1,955	687
Revenue growth %	-12%	63%	-8%	100%	78%	185%	n.m.
Gross profit	498	820	1,081	1,519	3,147	1,792	497
Gross margin	64%	92%	71%	92%	90%	92%	72%
EBITDA	-5,372	-5,484	-9,865	-10,057	-19,027	-17,745	-18,196
Operating loss	-6,103	-6,070	-11,251	-11,183	-21,409	-19,705	-19,423
Loss for the period	-6,804	-6,058	-11,295	-11,352	-22,075	-19,690	-19,441
Basic EPS (EUR)	-0.09	-0.08	-0.14	-0.15	-0.29	-0.29	-0.35
Net debt	-50,327	-75,727	-50,327	-75,727	-61,807	-68,070	-54,156
Net debt excluding lease liabilities	-56,843	-83,003	-56,843	-83,003	-68,740	-75,733	-59,977
Investments in property, plant, and equipment	-766	-2,759	-2,428	-5,063	-8,965	-7,737	-2,336
Operative free cash flow	-6,138	-8,243	-12,293	-15,120	-27,992	-25,482	-20,532
Cash and cash equivalents excluding short-term government bonds (end of period)	43,910	83,003	43,910	83,003	68,740	75,733	61,025
Cash and cash equivalents including short-term government bonds (end of period)	56,843	83,003	56,843	83,003	68,740	75,733	61,025

Operational KPI's

	4-6/2023	4-6/2022	1-6/2023	1-6/2022	1-12/2022	1-12/2021	1-12/2020
Number of new customer projects signed during the period							
Non-GMP	10	5	16	13	17	16	10
GMP	1		1		1	2	
Total number of new customer projects	**11**	**5**	**17**	**13**	**18**	**18**	**10**
Number of lines (end of the period)							
Non-GMP	19	16	19	16	18	14	8
GMP	1	1	1	1	1	1	1
Total number of lines (end of period)	**20**	**17**	**20**	**17**	**19**	**15**	**9**
Number of employees (end of the period)	158	143	158	143	150	125	74

Income Statement

Consolidated statement of comprehensive income

EUR thousand	Note	4-6/2023	4-6/2022	1-6/2023	1-6/2022	1-12/2022
Revenue	4	780	890	1,524	1,650	3,487
Other operating income						
Materials and services		-282	-70	-443	-131	-340
Employee benefits	7	-3,822	-4,160	-7,289	-7,636	-14,010
Depreciation, amortization, and impairment losses	6	-731	-586	-1,387	-1,127	-2,382
Other operating expenses	5	-2,048	-2,144	-3,657	-3,939	-8,164
Total expenses		**-6,883**	**-6,960**	**-12,776**	**-12,833**	**-24,896**
Operating loss		**-6,103**	**-6,070**	**-11,251**	**-11,183**	**-21,409**
Finance income		798	263	3,131	495	957
Finance expenses		-1,493	-248	-3,165	-647	-1,604
Total finance income and expenses		**-695**	**15**	**-35**	**-152**	**-647**
Loss before tax		**-6,798**	**-6,055**	**-11,286**	**-11,335**	**-22,056**
Income tax		-7	-4	-9	-16	-19
Loss for the period		**-6,804**	**-6,058**	**-11,295**	**-11,352**	**-22,075**

1-6/2023 comments

- Revenue fell by 8 % to EUR 1,524 thousand (1,650) as a result of slower project intake during 2H22. The revenue stemmed from 28 different customer projects (28 projects in 1H22). Revenues are recognized over the lifetime of the projects, based on expenses (mostly hours worked) booked for the projects.
- The gross profit fell to EUR 1,081 thousand (1,519), while the gross margin fell to 71% (92%). Excluding external GMP QC costs related to project Blockbuster, the gross margin was roughly 95%.
- The operating free cash flow improved by 19% to EUR –12.3m (-15.1m), helped by lower investments in property, plant and equipment (EUR 2.4m vs 5.1m). Operating costs, excluding depreciation, fell compared with 1H22.
- Cash position (incl. T-bills) was EUR 56.8 million (EUR 83.0) at the end of 2Q23.

5. Other operating expenses

The decrease in other operating expenses stems mainly from the decrease in IT expenses (SAP S4/ HANA was implemented in early January 2023).

EUR thousand	4-6/2023	4-6/2022	1-6/2023	1-6/2022	1-12/2022
Premises expenses	68	32	122	63	159
IT expenses	291	798	625	1,189	2,064
Marketing and communication expenses	118	175	265	342	825
Consultant and professional fees	332	270	658	639	1,355
Travel expenses	86	107	213	167	353
Voluntary personnel related expenses	161	226	353	413	781
R&D expenses - external	425	136	544	366	1,008
Other expenses	565	400	877	760	1,620
Total	**2,048**	**2,144**	**3,657**	**3,939**	**8,164**



www.nanoform.com

San Diego - New York - Lisbon - Oxford – London - Cambridge - Bordeaux - Stockholm - Helsinki


APPENDIX

CESS® Superior to Existing Technologies

	Controlled Expansion of Supercritical Solutions (CESS®)	Solid dispersion (e.g. spray drying)	Jet milling	Nanomilling
Description	Extracts API from supercritical CO_2 by applying controlled reduction in pressure	API is dispersed into a solid material, which dissolves when exposed to an aqueous media	Application of energy to physically break down API particles to finer ones	API particle size is reduced in a liquid vehicle via grinding
Particle size	Down to 10nm	300nm-25µm	800nm-10µm	>150nm
Particle formation	Controlled crystalline or amorphous and stable	Amorphous (unstable without excipients)	Unstable (crystalline and amorphous structures)	Unstable (crystalline and amorphous – needs excipient to stabilise)
Ease of formulation	✓	✗	✗	✗
Reproducibility	✓	✓	✗	✗
Free from excipients and solvents	✓	✗	✓	✗
Yield	High	Low	High	Low
Investment	Low	High	Low	Low

Source: Company information; Chimica Oggi: Chemistry Today; Roots Analysis, Pharmaceutical Spray Drying Market, 2014-2024

Nanoform from June 2020 IPO to June 2023

	IPO June 2020	*June 2023*	*Growth*
Employees	**50**	**~160**	**~3x**
Manufacturing lines	**5**	**~20**	**~4x**
Customers enrolled	**5**	**~40**	**~8x**
Customer projects started	**5**	**~60**	**~12x**

Nanoform customer projects – therapy area overview*

Pre-Clinical	Phase I	Phase II & III	Marketed
Cardiology	Immunology/ Inflammation	Metabolism and Endocrinology	Infectious Disease
Gastroenterology	Dermatology	Neurology (CNS)	Immunology/ Inflammation
Immunology/ Inflammation	Neurology (CNS)		Oncology
Infectious Disease	Oncology		Opthalmology
Metabolism and Endocrinology	Opthalmology		
Neurology (CNS)	Pain		
Oncology			
Opthalmology			
Respiratory			

Small is sustainable

Climate change is an environmental and a public health challenge. The healthcare sector accounts for ~5% of global greenhouse gas emissions, the equivalent of a small country. The pharmaceutical industry has an obligation to innovate and evolve, placing sustainability at the forefront.

Download Nanoform Sustainability Ebook here:

https://nanoform.com/en/sustainability-ebook/

Major pharma client quote:

"CESS® could be the green alternative to spray drying"*

starmap
Illuminating the future of Pharma ®

STARMAP® enables us to screen thousands of APIs simultaneously to see which are likely to be the stars that will shine the brightest. Partners are using the system not only to identify the potential for new chemical entities, but also to open up the possibility of revisiting and repurposing previously disregarded drug candidates where nanoforming will give them a second chance. Find out more here:

https://nanoform.com/en/technologies-and-services/starmap/

small is green

Small is lean through digital

The emergence of innovative artificial intelligence (AI) technologies is transforming the pharmaceutical industry. Nanoform's AI engine, STARMAP® has the capability to accelerate drug development with sustainability in mind by optimizing manufacturing processes and enhancing resource efficiency.

STARMAP® is the digital twin of our CESS® process; it leverages cutting-edge AI to predict the likely success of drug candidate molecules in our hands.

STARMAP® therefore ensures we can target only those projects we know will have the greatest chance of success, avoiding the waste of laboratory resources.

Nanoform educational material

VIDEOS

PODD 2022 Video – "How drug delivery is enabling a clinical trial for Glioblastoma" – TargTex CEO João Seixas and Nanoform CCO Christian Jones present promising data enabled by a nanoformed drug product for the treatment of glioblastoma multiforme (GBM): https://player.vimeo.com/video/791949368

American Association of Pharmaceutical Scientists (AAPS) webinar – We hosted a webinar "**Tailored API Nanoparticles: How Powerful Can Small Be?"** in partnership with the American Association of Pharmaceutical Scientists (AAPS): https://player.vimeo.com/video/684197206?h=6dac8c956d

Nanoform's Collaboration with TargTex Video – TargTex CEO João Seixas discusses the value Nanoform's CESS® technology delivered for TargTex's novel drug candidate targeting glioblastoma: https://nanoform.com/en/nanoforms-collaboration-with-targtex-2/

ADHD Awareness Month – How can STARMAP® Online guide the way? – In recognition of ADHD Awareness Month, we discuss the value our nanoparticle technology can bring to novel medicines for ADHD: https://player.vimeo.com/video/768531631

BOS 2023 Video – Nanoforming – the Patient- and Planet-Centric Approach From Increasing Bioavailability to Enabling Sustained Drug Delivery – Nanoform CCO Christian Jones delves into the benefits that can be unlocked for both patients and the planet through the Nanoform toolbox, supported by data from relevant case studies: https://nanoform.com/en/nanoforming-the-patient-and-planet-centric-approach-from-increasing-bioavailability-to-enabling-sustained-drug-delivery/

Drug Hunter Webinar – Not Your Grandparents' Drugs: How Approved Drugs Have Evolved Since the 70's – Nanoform & Drug Hunter explore how the lipophilicity (LogP) of drugs has changed over time: https://nanoform.com/en/not-your-grandparents-drugs-how-approved-drugs-have-evolved-since-the-70s/

ARTICLES & OTHER MATERIALS

Streamlining Drug Development with AI – Nanoform delved into this topic in CHEManager. Discover the company's insights here, including how Nanoform's pioneering AI-based STARMAP® platform can help: https://www.chemanager-online.com/en/news/nanoparticle-engineering

Small is Powerful: A Globally Unique Capability for Nanoforming HPAPIs – Nanoform discusses high-potency API handling capabilities with DCAT Value Chain Insights: https://www.dcatvci.org/sponsored/small-is-powerful-a-globally-unique-capability-for-nanoforming-hpapis/

Celanese Case Study – Nanoform and Celanese use drug nanoparticles to modify the release kinetics of ethylene vinyl acetate long-acting implants: https://nanoform.com/en/nanoform-and-celanese-use-drug-nanoparticles-to-modify-the-release-kinetics-of-ethylene-vinyl-acetate-long-acting-implants/

Nanoform White Paper – "Strategies for patient-centric differentiation through the USFDA 505(b)(2) pathway" – With faster routes to approval, the volume of 505(b)(2) applications now exceeds that of 505(b)(1). Discover the reasons for this in our white paper: https://nanoform.com/en/wp-content/uploads/sites/2/2022/05/whitepaper-march-2022.pdf

PION Partnership – Characterization of the Flux Performance of Nanoformed and Untreated Crystalline Piroxicam Solid Suspensions, and the Relative Contributions of the Particle Drifting Effect to In Vitro Flux – Nanoform and PION performed MicroFLUX analysis on nanoformed piroxicam to investigate nanoparticle flux performance compared to crystalline solid suspensions: https://nanoform.com/en/wp-content/uploads/sites/2/2023/07/Nanoform-Poster-91-x-91-cm-V7.pdf

Nanoform Sustainability Ebook – Discover how we are driving sustainability across the pharmaceutical industry in our ebook: https://nanoform.com/en/sustainability-ebook/

Nanoform Brochure to the Pharma Industry – https://nanoform.com/en/brochure/

Selection of Nanoform Institutional Shareholders

“Not Your Grandparents’ Drugs”

How Drugs Changed Since the 70’s and What to Do About It:

https://www.youtube.com/watch?v=nXcs3Irk7Q0

Dr. Dennis Hu

CEO

Christian Jones, FRSC **Chief Commercial Officer Nanoform**

Dr. Chris Worrall

Vice President

US Business Development

Nanoform

FINANCIAL CALENDAR

- Aug 24, 2023 - Q2 2023 interim report
- Aug 24, 2023 - Financial Hearings webcast presentation at 15.00 EEST: https://ir.financialhearings.com/nanoform-q2-2023
- Sep 4, 2023 - Presentation and 1-1 ‘s at SEB Stockholm (in person)
- Sep 5, 2023 - Presentation at Danske Bank (digital)
- Nov 22, 2023 - Q2 2023 interim report
- Nov 22, 2023 - Financial Hearings webcast presentation at 15.00 EEST
- Nov 23, 2023 - Presentation and 1-1’s at SEB Healthcare Seminar, Stockholm (in person)
- Dec 14, 2023 - Presentation and 1-1’s at DNB Nordic Healthcare Seminar, Oslo (in person)

FURTHER ENQUIRIES

- CFO Albert Hæggström, albert.haeggstrom@nanoform.com, +358 29 370 0150
- DIR Henri von Haartman, hvh@nanoform.com, +46 76866 50 11